Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Acute myeloid leukaemia

    EU flag

    CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

    The new formulation would allow blood cancer patients to halve their daily pill intake

    - PMLiVE

    GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

    Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

    - PMLiVE

    J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

    More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

    Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

    - PMLiVE

    Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

    B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

    - PMLiVE

    ICR researchers uncover new method for predicting bowel cancer risk in IBD patients

    Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis

    - PMLiVE

    ICR researchers uncover genes responsible for tumour progression in prostate cancer

    The findings could pave the way for new treatment approaches that improve patient outcomes

    - PMLiVE

    AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

    SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer

    - PMLiVE

    ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

    The research could pave the way for the development of new drugs that prevent drug resistance

    - PMLiVE

    ICR researchers identify potential treatment approach for acute myeloid leukaemia

    More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

    - PMLiVE

    ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients

    More than 130,000 patients are treated with radiotherapy on the NHS every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links